SCHEDULE: Ally Bridge Group Discloses 11.8% Stake in ProMIS

Ally Bridge Group entities and Fan Yu have disclosed a beneficial ownership of 11.8% in ProMIS Neurosciences Inc., totaling 6,058,738 common shares.

Summary

• ABG Management Ltd., Ally Bridge Group (NY) LLC, Ally Bridge MedAlpha Master Fund L.P., and Mr. Fan Yu collectively reported beneficial ownership of 6,058,738 common shares of ProMIS Neurosciences Inc.
• This ownership represents 11.8% of the outstanding common shares of ProMIS Neurosciences Inc.
• The percentage is calculated based on 51,511,310 common shares outstanding as of July 29, 2025.
• The reported amount does not include an additional 9,690,037 common shares issuable upon the exercise of warrants held by Ally Bridge MedAlpha Master Fund L.P., which are subject to exercise limitations.
• Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, managing the investments of Ally Bridge MedAlpha Master Fund L.P.

Sentiment

Score: 6

Explanation: The filing is a standard beneficial ownership disclosure, indicating a significant stake by an investment group. While not inherently positive or negative, a substantial investment by a specialized fund can be viewed as a vote of confidence, hence a slightly positive sentiment.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates a significant investment by Ally Bridge Group, a healthcare-focused investment firm, in ProMIS Neurosciences, a biotechnology company. Such investments can signal confidence in the company's long-term prospects within the neuroscience and drug development sector.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional investor holding a substantial stake may influence investor perception and potentially stock liquidity.
• Company Management: Awareness of a large shareholder may influence strategic decisions, although the filing explicitly states the stake is not for control purposes.

Key Dates

Keywords

ProMIS Neurosciences, Ally Bridge Group, Fan Yu, Beneficial Ownership, Common Shares, Biotechnology, Neuroscience, Investment, SEC Filing, Schedule 13G